tbuckley/cabot-search huggingface dataset:
Preclinical Evidence That 3′-Deoxy-3′-[18F]Fluorothymidine PET Can Visualize Recovery of Hematopoiesis after Gemcitabine Chemotherapy
Authors: Sonja Schelhaas, Annelena Held, Nicole Bäumer, Thomas Viel, Sven Hermann, Carsten Müller-Tidow, Andreas H. Jacobs
Journal: Cancer Research (2016)

Abstract Molecular imaging with the PET tracer 3′-deoxy-3′-[18F]fluorothymidine ([18F]FLT) allows assessment of the proliferative state of organs in vivo. Although used primarily in the oncology clinic, it can also shed light on the proliferation of other tissues, as demonstrated here for monitoring hematopoietic organs that recover after myelosuppressive chemotherapy. In the NMRI nude mouse model, we observed up to a 4.5-fold increase in [18F]FLT uptake in bone marrow and spleen on days 2, 3, and 5 after treatment with gemcitabine, a chemotherapeutic agent that is powerfully myelosuppressive in the model. Specifically, we observed (i) a reduced spleen weight; (ii) reduced bone marrow cell counts and proliferation (BrdUrd flow cytometry, spleen IHC; 6 hours/day 1); and (iii) reduced leukocytes in peripheral blood (day 5). In conclusion, our results show how [18F]FLT PET can provide a powerful tool to noninvasively visualize the proliferative status of hematopoietic organs after myelosuppressive therapy. Cancer Res; 76(24); 7089–95. ©2016 AACR.
Late Onset of Secondary AML with 5q- in CLL with 13q- Abnormality; Coexistence of the Two Neoplastic Clones and the Therapeutic Potential of Lenalidomide.
Authors: Imma Attolico, Giancarlo Discepoli, Roberta Nuccorini, Sara Pascale, Sabrina Coluzzi, Michele Pizzuti, Angela Amendola, Attilio Olivieri
Journal: Blood (2009)
<i>IDH2</i> Mutations Define a Unique Subtype of Breast Cancer with Altered Nuclear Polarity
Authors: Sarah Chiang, Britta Weigelt, Huei-Chi Wen, Fresia Pareja, Ashwini Raghavendra, Luciano G. Martelotto, Kathleen A. Burke, Thais Basili, Anqi Li, Felipe C. Geyer, Salvatore Piscuoglio, Charlotte K.Y. Ng, Achim A. Jungbluth, Jörg Balss, Stefan Pusch, Gabrielle M. Baker, Kimberly S. Cole, Andreas von Deimling, Julie M. Batten, Jonathan D. Marotti, Hwei-Choo Soh, Benjamin L. McCalip, Jonathan Serrano, Raymond S. Lim, Kalliopi P. Siziopikou, Song Lu, Xiaolong Liu, Tarek Hammour, Edi Brogi, Matija Snuderl, A. John Iafrate, Jorge S. Reis-Filho, Stuart J. Schnitt
Journal: Cancer Research (2016)

Abstract Solid papillary carcinoma with reverse polarity (SPCRP) is a rare breast cancer subtype with an obscure etiology. In this study, we sought to describe its unique histopathologic features and to identify the genetic alterations that underpin SPCRP using massively parallel whole-exome and targeted sequencing. The morphologic and immunohistochemical features of SPCRP support the invasive nature of this subtype. Ten of 13 (77%) SPCRPs harbored hotspot mutations at R172 of the isocitrate dehydrogenase IDH2, of which 8 of 10 displayed concurrent pathogenic mutations affecting PIK3CA or PIK3R1. One of the IDH2 wild-type SPCRPs harbored a TET2 Q548* truncating mutation coupled with a PIK3CA H1047R hotspot mutation. Functional studies demonstrated that IDH2 and PIK3CA hotspot mutations are likely drivers of SPCRP, resulting in its reversed nuclear polarization phenotype. Our results offer a molecular definition of SPCRP as a distinct breast cancer subtype. Concurrent IDH2 and PIK3CA mutations may help diagnose SPCRP and possibly direct effective treatment. Cancer Res; 76(24); 7118–29. ©2016 AACR.
Construction and targeting of a 5F11-scFv-methioninase fusion protein for antibody-directed enzyme pro-drug therapy (ADEPT) against neuroblastoma
Authors: J. Hu, H. Guo, H. Xu, N. V. Cheung
Journal: Journal of Clinical Oncology (2007)

3043 Background: Recombinant methioninase (METase) depletes methionine and inhibits tumor growth in preclinical models. 5F11 single-chain variable fragment (scFv) can target fusion proteins (e.g. streptavidin (SA), J. Nucl. Med., 45:867, 2004) preferentially to GD2- positive human neuroblastoma (NB). METase targeted to tumors may release methylselenol from the prodrug selenomethionine for tumor therapy. Methods: 5F11-scFv gene fused upstream of METase in pKK-223–3 to form 5F11-scFv-METase. Fusion protein produced in E. coli and purified by chromatography and endotoxin removal retained enzyme activity. Binding of 5F11-scFv-METase to tumor cells was assayed by indirect immunofluorescence and binding kinetics to GD2 analyzed by surface plasmon resonance. Cytotoxicity against human NB cell lines LAN-1, NMB-7 and SK-N-ER was tested using proliferation inhibition and apoptosis assays. Targeting to NB xenografts was studied by biodistribution using 125 I-anti-idiotype 1G8 as the secondary tracking antibody. Results: 5F11-scFv-METase was purified to 84% and 94.1% homogeneity by SDS-PAGE and HPLC, respectively. Enzyme activity was 3.6 units/mg protein. Its avidity (K D =1.72×10 -7 M) as a dimer compared favorably with the monomeric 5F11-scFv (K D =1.07×10 - 7 M) and tetrameric 5F11-scFv-SA (K D =2.62×10 -9 M). Immunofluorescent staining of 5F11-scFv-METase was comparable to 5F11-scFv-SA for LAN-1 and NMB-7. In the presence of 20 μM selenomethionine, IC 50 of 5F11-scFv-METase was 0.03, 0.02 and 0.02 units/ml for LAN-1, NMB-7 and SK-N-ER, respectively. When treated with 0.3 units/ml of 5F11-scFv-METase and 20 μM selenomethionine, apoptosis was induced in SK-N-ER by 8 hours, peaking at 24 hours. In biodistribution studies, tumor uptake in LAN-1 xenograft averaged 4.07±0.6% injected dose per gram at 48 hours. Conclusions: 5F11-scFv-METase fusion protein retains enzyme activity and immunoreactivity. It targets to tumors in vivo and activates the pro-drug selenomethionine to effect tumor cytotoxicity. Its potential for tumor-selective methionine depletion as well as in ADEPT applications deserves further studies. No significant financial relationships to disclose.
Clinical Significance of Immunoglobulin Isotype Switching in Patients with Multiple Myeloma
Authors: Jae-Cheol Jo, Dok Hyun Yoon, Shin Kim, Kyoungmin Lee, Eun Hee Kang, Seongsoo Jang, Chan-Jeoung Park, Hyun Sook Chi, Jooryung Huh, Chan-Sik Park, Cheolwon Suh
Journal: Blood (2012)
Increased Dose Intensity of SGN-33, a Humanized Monoclonal Antibody Targeting CD33, Is Active and Well-Tolerated in Patients with Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS).
Authors: Azra Raza, Joseph G. Jurcic, Gail J. Roboz, Joseph J. Stephenson, Mark U. Rarick, Brent L. Wood, Laurie E. Grove, Eric L. Sievers, Jonathan G. Drachman
Journal: Blood (2006)
Abstract A29: Effects of obesity on regulation of macrophage population in the prostate tumor microenvironment
Authors: Gloria C. Galvan, Shruti Apte, Linda A. deGraffenried
Journal: Cancer Research (2016)

Abstract Background: Obesity is associated with a greater risk of prostate cancer mortality, but the mechanisms driving this progression are still unclear. A high concentration of macrophages within the tumor microenvironment, especially tumor-associated macrophages (TAMs), has been linked to progression and metastasis in numerous cancer types, including prostate. Obesity increases circulating levels of monocyte chemotactic protein-1 (MCP-1), a chemokine involved in monocyte migration. In addition, prostaglandin E2 (PGE2), a molecule closely associated with obesity, appears to be involved in macrophage polarization. Our preliminary in vitro data suggest that obese conditions promote both macrophage recruitment and TAM polarization. Hypothesis: Based upon these preliminary results, we hypothesize that obesity-induced prostate cancer progression is due, in part, to increased TAM concentrations in the prostate tumor micro-environment, promoting pro-metastatic signaling. Methods: In order to mimic the prostate tumor microenvironment, an in vitro model composed of adipose stromal cells, macrophages, prostate cancer epithelial cells and sera from obese and non-obese men was used to assess the impact of obesity on the paracrine signaling network. Matrigel invasion chambers were used to assess macrophage recruitment. qPCR was used to measure mRNA levels of proteins associated with a TAM phenotype as well as mRNA levels of MCP-1 and cyclooxygenase-2 (COX-2), an enzyme involved in PGE2 production. Results: Obese conditions resulted in increased macrophage recruitment and increased mRNA levels of TAM markers in macrophages. Furthermore, MCP-1 mRNA levels in adipose stromal cells and prostate cancer cells were higher under obese conditions compared to non-obese conditions. Similarly, obese conditions increased COX-2 mRNA levels in prostate cancer cells. Conclusions: Data from our in vitro study suggest that obesity may promote macrophage infiltration into the prostate tumor microenvironment and play a role in macrophage polarization towards a tumor-associated phenotype. This study will potentially serve to determine the value of macrophage and TAM concentration as biomarkers in this patient population, and lay the foundation for future studies investigating whether this phenomenon might be an effective therapeutic target. Citation Format: Gloria C. Galvan, Shruti Apte, Linda A. deGraffenried. Effects of obesity on regulation of macrophage population in the prostate tumor microenvironment. [abstract]. In: Proceedings of the AACR Special Conference: Function of Tumor Microenvironment in Cancer Progression; 2016 Jan 7–10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2016;76(15 Suppl):Abstract nr A29.
A New Polycythemia Syndrome: Congenital Polycythemia with High Erythropoietin and Propensity for Malignant Hypertension Due to Paraganglioma.
Authors: Yongli Guan, John K. Wu, Wasil Jastaniah, Larry G. Moss, Colleen Digman, Salvatore Mostacci, Jaroslav F. Prchal, Josef T. Prchal
Journal: Blood (2004)
Toxicity of epirubicin and cyclophosphamide (EC) vs. docetaxel (D) followed by EC in the adjuvant (adj) treatment of node positive breast cancer. A multicenter randomized phase III study (GOIM9902)
Authors: M. Lopez, M. Brandi, P. Foggi, F. Giotta, N. Gebbia, B. Massidda, G. Filippelli, G. Cicero, P. Vici, G. Colucci
Journal: Journal of Clinical Oncology (2006)

10526 Background: Due to high activity of taxanes (T) and anthracyclines (A) in advanced breast cancer (BC) and to the lack of cross-resistance between them, several adjuvant (adj) trials have been performed to test the efficacy of combination or sequential schedules of T and A adjuvant. In most of the sequential trials A followed T. The sequence T-&gt;A was proven active in metastatic BC, but no data are available in the adj setting. This multicenter randomized phase III study was designed to evaluate the efficacy of the sequence T-&gt;A vs an A containing regimen Methods: Pts with pT1–3 pN1 M0 (UICC1997) BC, age 18–70, PS(ECOG) 0–1, normal cardiac function, adequate bone marrow, hepatic and renal function were eligible for the study. Pts were stratified according to institution, age (≤ 50 vs &gt; 50), hormonal receptor status and number of involved nodes (≤ 3, 4–9, ≥ 10) and were randomized to receive either 4 cycles of EC (Epirubicin 120 mg/m 2 + Cyclophosphamide 600 mg/m 2 on day 1 q21) in arm A or 4 cycles of D (100 mg/m 2 on day 1 q21) followed by 4 cycles of EC in arm B. Primary endpoint was DFS. Secondary endpoints OS and toxicity. Results: Between april 1999 and october 2005, 750 pts were enrolled (374 in arm A and 376 in arm B) in 25 Italian institutions. Pts characteristics are as follows: Arm A: age ≤ 50 yrs 185/374; ≤ 3 nodes 182/374, 4–9 nodes 129/374, ≥ 10 nodes 63/374; positive HR 287/374 Arm B: age ≤ 50 yrs 197/376; ≤ 3 nodes 184/376, 4–9 nodes 131/376, ≥ 10 nodes 61/376; positive HR 289/376 Toxicity data (Arm A vs Arm B) of the first 495(241/254) pts are the following: Neutropenia G3 (29% vs 21.3%), neutropenia G4 (32.7% vs 48.8%), febrile neutropenia G3–4 (3.7% vs 9.5%), thrombocytopenia G3–4 (3.3% vs 1.6%), anemia G3 (0% vs 2.4%), N/V G3–4 (6.2% vs 3.1%), mucositis G3–4 (3.7% vs 3.9%), diarrhea G3–4 (0.4% vs 2.8%), peripheral neuropathy G1–3 (0% vs 9.9%), hypersensitivity reactions G3–4 (0% vs 4.3%), cardiac toxicity G3 (0.4% vs 0%) Conclusions: Treatment was generally well tollerated in both arms with a higher incidence of neutropenia, usually short lasting, in arm B. The use of prophylactic G-CSF in those patients experiencing neutropenia G3–4 may be advisable. There were no significant differences in cardiac toxicity. No significant financial relationships to disclose.
Оксидантно-протиоксидантний гомеостаз при гастродуоденопатіях, індукованих нестероїдними протизапальними препаратами, у хворих на остеоартроз з урахуванням патогенних штамів Helicobacter pylori
Authors: L.M. Honcharuk, O.I. Fediv, Yu.V. Kohanuk
Journal: GASTROENTEROLOGY (2016)

Роль Helicobacter pylori (Hp) в патогенетичних механізмах розвитку гастродуоденопатій (ГДП), обумовлених нестероїдними протизапальними препаратами (НПЗП), у хворих на остеоартроз (ОА) є не­однозначною. Метою роботи було визначення зміни оксидантно-протиоксидантного гомеостазу при ГПД, індукованих НПЗП, у хворих на ОА залежно від наявності патогенних штамів Hp. Методи. Для виконання поставленої мети обстежено 68 хворих на ОА із супутніми Hp-асоційованими ГДП, індукованими НПЗП. Визначено штами Hp у калі, крові та біоптатах методом полімеразної ланцюгової реакції. Досліджено вміст продуктів окиснювальної модифікації білків — альдегід- і кетондинітрофенілгідразонів нейтрального характеру (АКДНФГ НХ), глутатіону відновленого (ГВ), активності глутатіонпероксидази (ГП) та глутатіон-S-трансферази (ГТ). Результати. В усіх обстежених пацієнтів спостерігали вірогідне зростання інтенсивності окиснювальної модифікації білків. Однак у хворих із супутнім Нр патогенним та ульцерогенним штамом cag A+/vac A+ АКДНФГ НХ були відповідно вище на 13,55 % (р &lt; 0,05) та 22,89 % (р &lt; 0,05) порівняно з хворими із супутніми Нр cag A+/vac A– та Нр cag A–/vac A+. В обстежених хворих спостерігалося зниження вмісту ГВ на тлі компенсаторного зростання активності ГТ і ГП. У досліджуваних із Нр патогенним та ульцерогенним штамом cag A+/vac A+ вміст ГВ був вірогідно нижчим відповідно на 16,45 та 26,66 % порівняно з хворими із супутніми Нр cag A+/vac A– та Нр cag A–/vac A+. Активність ГТ і ГП у хворих із Нр, що містили штами cag A+/vac A–, були дещо вищими, ніж у пацієнтів із Нр, що містили штами cag A–/vac A+. Висновок. При гастродуоденопатіях, індукованих НПЗП, у хворих на ОА спостерігаються вірогідні зміни оксидантно-протиоксидантного гомеостазу, а супутній патогенний та ульцерогенний штам Hp cag A+/vac A+ сприяє інтенсифікації окиснювальної модифікації білків на тлі порушення функціонування системи протиоксидантного захисту.
A phase II trial of thalidomide (Thal) and procarbazine (Pro) in adults with recurrent or progressive malignant gliomas (MG)
Authors: G. J. Lesser, V. Stieber, D. Case, G. Enevold, R. Rosdhal, S. Tatter, T. Ellis, K. McMullen, E. Shaw
Journal: Journal of Clinical Oncology (2007)

2067 Background: Thal and Pro are among the few agents with demonstrated activity against MG. A two-stage, phase II trial was initiated within the WFURB to establish the response rate of combination Thal-Pro in patients (pts) with recurrent or progressive MG. Methods: Eligibility included pt age = 18 with measurable tumor on contrast enhanced brain scans; KPS = 60; normal liver, kidney and hematologic function; and treatment with = 2 prior regimens. Pts were required to participate in the S.T.E.P.S. Program and mandated to comply with agreed upon measures to avoid conception. Protocol therapy included Pro 250mg/m 2 /d x 5d q 28days and Thal 200mg/day continuously. Intrapatient dose escalation of Thal was attempted (increase by 100mg/day weekly as tolerated) to a maximum of 800mg/day. All pts received daily pyridoxine(100mg), warfarin(1mg) and stool softeners/laxatives. MRI/CT scans were performed prior to each odd cycle (every 8 weeks) to assess response based upon changes in the products of the largest bidimensional tumor diameters. Quality of life questionnaires including the FACT-Br were performed at baseline and prior to each odd cycle in all treated pts. Results: 18 pts (11 male) were enrolled (median age 50, range 27–63). One pt refused any therapy and is excluded from the analysis. The 17 treated pts received 36 cycles (median 2) of therapy. The median maximum Thal dose achieved was 400mg (range 200–800). No complete or partial responses were seen; 1 pt (6%) experienced stable disease, 14 (82%) progressed as best response and 2 (12%) were not evaluable for response. Median time to progression was 2.1 months (95% CI, 1.5–2.5). 14 pts have died; median survival was 7.6 months (95% CI, 3.5–9.4). Grade 3/4 drug related toxicity was minimal. Conclusions: Despite modest individual response rates in multiple prior phase II and III trials, the combination of Pro and Thal demonstrated no efficacy in this trial and this combination is unworthy of further investigation in pts with MG. Supported by NCI 1 U10 CA81851 and Celgene. No significant financial relationships to disclose.
Deep Retinal Layer Microvasculature Dropout Detected by the Optical Coherence Tomography Angiography in Glaucoma
Authors: Min Hee Suh, Linda M. Zangwill, Patricia Isabel C. Manalastas, Akram Belghith, Adeleh Yarmohammadi, Felipe A. Medeiros, Alberto Diniz-Filho, Luke J. Saunders, Robert N. Weinreb
Journal: Ophthalmology (2016)
Redirected EBV-Specific Stem Cell-Memory and Central-Memory CD8+ T Lymphocytes Exhibit Effective and Sustained Antileukemic Immunity to Acute Myeloid Leukemia in a Patient-Tailored Humanized NSG Mouse Model
Authors: Udo F. Hartwig, Iuliia Weber, Janina Petry, Shamsul A. Khan, Andreas Mades, Matthias Theobald
Journal: Blood (2014)
GW26-e1830 Effects of Unilateral Noninvasive Vagus Nerve Stimulation on the Left Ventricular Post-Ischemic Remodeling
Authors: Zhuo Wang, Xiaoya Zhou, Songyun Wang, Mingxian Chen, Bing Huang, Kai Liao, Lilei Yu, Hong Jiang
Journal: Journal of the American College of Cardiology (2015)
Treatment with Oral Melphalan and Dexamethasone of An Extended Patient Population with AL Amyloidosis.
Authors: Giovanni Palladini, Paola Russo, Andrea Foli, Letizia Zenone Bragotti, Francesca Lavatelli, Vittorio Perfetti, Laura Obici, Stefano Perlini, Giampaolo Merlini
Journal: Blood (2009)
GW26-e1573 Apelin: An Endogenous Peptide Essential for Cardiomyogenic Differentiation of Mesenchymal Stem Cells via Activating Extracellular Signal-Regulated Kinase 1/2 and 5
Authors: Li Wang, Zhiming Zhu, Ningkun Zhang, Zhirong Fang, Lianru Gao
Journal: Journal of the American College of Cardiology (2015)
GW26-e0197 Exploring the Active Ingredients in Chinese Yellow Wine Which Could Inhibit the Progress of Atherosclerosis in LDLR Knockout Mice
Authors: Liping Meng, Xiaoya Zhai, Chenjian Jiang, Zheng Ji, Yan Guo, Jufang Chi, Hangyuan Guo
Journal: Journal of the American College of Cardiology (2015)
Remission Status and Performance Status, but Not Cytogenetic Risk Group, Are Associated with Outcome After Reduced Intensity Conditioning (RIC) and Allogeneic Hematopoietic Cell Transplantation (HCT) for Therapy-Related Myeloid Neoplasms (t-MN): Results of the University of Chicago Experience.
Authors: Vaishalee P. Kenkre, Sarah Horowitz, Richard A. Larson, Andrew Artz, Elizabeth Shima Rich, Yanming Zhang, Michelle M. Le Beau, Lucy A Godley, Olatoyosi Odenike, Michael Thirman, Koen van Besien, Wendy Stock
Journal: Blood (2009)
Phase I Study for Poor Prognosis Lymphoma: Modification of the “BEAM” (BCNU +Etoposide+ARA-C+Melphalan) Regimen with Escalating-Dose Melphalan (MEL) Using Amifostine (AF) Cytoprotection and Autologous Hematopoietic Stem Cell Transplantation (AHSCT).
Authors: Gordon L. Phillips, Camille N. Abboud, Steven H. Bernstein, Jonathan W. Friedberg, Michael W. Becker, Jainulabdeen J. Ifthikharuddin, Faith Young, Jane L. Liesveld
Journal: Blood (2006)
Review: In renal failure, direct oral anticoagulants reduce risk for hemorrhagic stroke compared with VKAs
Authors: Dennis G. Maki
Journal: Annals of Internal Medicine (2016)

Source Citation Raccah BH, Perlman A, Danenberg HD, et al. Major bleeding and hemorrhagic stroke with direct oral anticoagulants in patients with renal failure: systematic review and meta-analysis of randomized trials. Chest. 2016;149:1516-24. 26836922
GW26-e0202 Expression of Matrix Metalloproteinase-2 and Mitogen-Activated Protein Kinases in Ascending Aortic Aneurysms and Aortic Valves of Patients with Bicuspid or Tricuspid Aortic Valves: a Comparative Study
Authors: Chunmao Wang, Xiaogang Sun, Xiangyang Qian, Qian Chang
Journal: Journal of the American College of Cardiology (2015)
GW26-e2329 A seven-period, self-crossover, open-label clinical trial to assess the effect of AEML on the Glycaemic Index of common carbohydrates
Authors: Yanfen Li, Lanjun Sun, Zhong Zhong, Ziqiang Li, Chen Xie, Ruihua Wang, Jinxia Sun, Bo Mi, Yuhong Huang
Journal: Journal of the American College of Cardiology (2015)
Long-term effect of COPD on patients with lung cancer
Authors: A. Panwalkar, A. Kessinger, F. Loberiza, A. Ganti
Journal: Journal of Clinical Oncology (2007)

18077 Background: Despite the association between chronic obstructive pulmonary disease (COPD) and lung cancer, their inter-relationship has not been studied. Their pathogenesis suggests that they may be a continuum of a single disease. The effect of COPD on outcomes in lung cancer has been primarily studied in surgical candidates in the peri-operative period, however long-term effects are unclear. We proposed to study the influence of COPD on overall survival in this patient population. Methods: After IRB approval a retrospective chart review was performed on patients with stage I and II, non-small cell lung carcinoma (NSCLC) diagnosed from 1994 through 2005. Data including demographics, smoking, treatment given, pulmonary function tests (PFTs) and survival were collected. Patients were classified as having COPD based on FEV1/FVC ratio of &lt; 70%, and further graded by the percentage of predicted FEV1 value. Overall survival was computed by multiple linear regression and the p-value was calculated using the chi-square test. Results: Of the 399 patients with early stage NSCLC, 107 had PFTs evaluated before treatment of the cancer. Of these 42 (39%) did not have COPD, while 65 (61%) had COPD. Patients with COPD presented with a later stage (IB or II) as compared to those without COPD. After adjusting for age, stage, histology, treatment or smoking history, there was no difference in the overall survival among the two groups. The probability of 2-year overall survival for patients with mild, moderate, severe and very severe COPD was 100%, 79%, 77% and 62% respectively, compared with 72% for those without COPD. (p = 0.64). Conclusions: Patients with COPD presented with a later stage (IB or II) as compared to those without COPD. Despite this there was a trend toward an improvement in overall survival in patients with mild to moderate COPD that underwent surgical resection. This may be related, in part, to the beneficial effects of volume reduction of the diseased lung. The data are limited by low power that may have led to insignificant results. Further larger studies are required to better assess the relationship between COPD and lung cancer and its long term effects. No significant financial relationships to disclose.
An Official American Thoracic Society/American College of Chest Physicians Clinical Practice Guideline: Liberation from Mechanical Ventilation in Critically Ill Adults. Rehabilitation Protocols, Ventilator Liberation Protocols, and Cuff Leak Tests
Authors: Timothy D. Girard, Waleed Alhazzani, John P. Kress, Daniel R. Ouellette, Gregory A. Schmidt, Jonathon D. Truwit, Suzanne M. Burns, Scott K. Epstein, Andres Esteban, Eddy Fan, Miguel Ferrer, Gilles L. Fraser, Michelle Ng Gong, Catherine L. Hough, Sangeeta Mehta, Rahul Nanchal, Sheena Patel, Amy J. Pawlik, William D. Schweickert, Curtis N. Sessler, Thomas Strøm, Kevin C. Wilson, Peter E. Morris
Journal: American Journal of Respiratory and Critical Care Medicine (2016)

Section:ChooseTop of pageAbstract <<ContentsSummary of Recommendation...IntroductionMethodsResults1SummaryReferencesCITING ARTICLES